SUPN logo

Supernus Pharmaceuticals (SUPN) Cash from investing

annual CFI:

-$189.87M-$458.60M(-170.65%)
December 31, 2024

Summary

  • As of today (June 3, 2025), SUPN annual cash flow from investing activities is -$189.87 million, with the most recent change of -$458.60 million (-170.65%) on December 31, 2024.
  • During the last 3 years, SUPN annual CFI has fallen by -$107.95 million (-131.79%).
  • SUPN annual CFI is now -170.65% below its all-time high of $268.73 million, reached on December 31, 2023.

Performance

SUPN Cash from investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSUPNcash flow metrics

quarterly CFI:

$37.32M+$49.95M(+395.28%)
March 31, 2025

Summary

  • As of today (June 3, 2025), SUPN quarterly cash flow from investing activities is $37.32 million, with the most recent change of +$49.95 million (+395.28%) on March 31, 2025.
  • Over the past year, SUPN quarterly CFI has increased by +$88.94 million (+172.29%).
  • SUPN quarterly CFI is now -84.44% below its all-time high of $239.78 million, reached on March 31, 2023.

Performance

SUPN quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSUPNcash flow metrics

TTM CFI:

-$100.93M+$88.94M(+46.84%)
March 31, 2025

Summary

  • As of today (June 3, 2025), SUPN TTM cash flow from investing activities is -$100.93 million, with the most recent change of +$88.94 million (+46.84%) on March 31, 2025.
  • Over the past year, SUPN TTM CFI has dropped by -$78.25 million (-345.10%).
  • SUPN TTM CFI is now -135.30% below its all-time high of $285.94 million, reached on September 30, 2023.

Performance

SUPN TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSUPNcash flow metrics

Cash from investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

SUPN Cash from investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-170.7%+172.3%-345.1%
3 y3 years-131.8%+153.3%-25.4%
5 y5 years-20.2%+5.3%-424.6%

SUPN Cash from investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-170.7%+12.4%-84.4%+145.4%-135.3%+58.5%
5 y5-year-170.7%+12.4%-84.4%+134.5%-135.3%+58.5%
alltimeall time-170.7%+54.1%-84.4%+108.8%-135.3%+80.3%

SUPN Cash from investing History

DateAnnualQuarterlyTTM
Mar 2025
-
$37.32M(-395.3%)
-$100.93M(-46.8%)
Dec 2024
-$189.87M(-170.7%)
-$12.64M(-83.6%)
-$189.87M(-21.9%)
Sep 2024
-
-$77.01M(+58.5%)
-$243.21M(+84.9%)
Jun 2024
-
-$48.59M(-5.9%)
-$131.56M(+480.2%)
Mar 2024
-
-$51.62M(-21.8%)
-$22.68M(-108.4%)
Dec 2023
$268.73M(-224.0%)
-$65.98M(-290.5%)
$268.73M(-6.0%)
Sep 2023
-
$34.63M(-42.6%)
$285.94M(+69.1%)
Jun 2023
-
$60.30M(-74.9%)
$169.08M(+81.6%)
Mar 2023
-
$239.78M(-591.7%)
$93.10M(-143.0%)
Dec 2022
-$216.66M(+164.5%)
-$48.77M(-40.7%)
-$216.66M(+136.1%)
Sep 2022
-
-$82.23M(+424.5%)
-$91.77M(+502.2%)
Jun 2022
-
-$15.68M(-77.6%)
-$15.24M(-81.1%)
Mar 2022
-
-$69.99M(-191.9%)
-$80.45M(-1.8%)
Dec 2021
-$81.91M(+136.1%)
$76.13M(-1434.7%)
-$81.91M(-24.6%)
Sep 2021
-
-$5.70M(-92.9%)
-$108.70M(-4.9%)
Jun 2021
-
-$80.89M(+13.2%)
-$114.30M(-19.3%)
Mar 2021
-
-$71.44M(-244.8%)
-$141.58M(+308.0%)
Dec 2020
-$34.70M(-78.0%)
$49.34M(-536.6%)
-$34.70M(-46.3%)
Sep 2020
-
-$11.30M(-89.6%)
-$64.61M(+4.8%)
Jun 2020
-
-$108.18M(-405.3%)
-$61.66M(+220.5%)
Mar 2020
-
$35.44M(+82.3%)
-$19.24M(-87.8%)
Dec 2019
-$157.92M(-61.8%)
$19.44M(-332.7%)
-$157.92M(+10.4%)
Sep 2019
-
-$8.36M(-87.3%)
-$143.03M(+30.8%)
Jun 2019
-
-$65.76M(-36.3%)
-$109.34M(-76.5%)
Mar 2019
-
-$103.25M(-400.7%)
-$465.72M(+12.6%)
Dec 2018
-$413.48M(+378.5%)
$34.33M(+35.5%)
-$413.48M(-11.4%)
Sep 2018
-
$25.34M(-106.0%)
-$466.94M(-9.1%)
Jun 2018
-
-$422.14M(+727.6%)
-$513.44M(+340.1%)
Mar 2018
-
-$51.01M(+166.7%)
-$116.66M(+35.0%)
Dec 2017
-$86.42M
-$19.13M(-9.6%)
-$86.42M(+6.8%)
DateAnnualQuarterlyTTM
Sep 2017
-
-$21.16M(-16.6%)
-$80.93M(+15.4%)
Jun 2017
-
-$25.36M(+22.2%)
-$70.12M(+52.2%)
Mar 2017
-
-$20.76M(+52.2%)
-$46.08M(+28.1%)
Dec 2016
-$35.96M(-8.5%)
-$13.64M(+31.8%)
-$35.96M(+2.2%)
Sep 2016
-
-$10.35M(+682.9%)
-$35.19M(+4.7%)
Jun 2016
-
-$1.32M(-87.6%)
-$33.60M(-13.4%)
Mar 2016
-
-$10.65M(-17.2%)
-$38.82M(-1.2%)
Dec 2015
-$39.29M(+1377.6%)
-$12.87M(+46.9%)
-$39.29M(+14.3%)
Sep 2015
-
-$8.76M(+33.9%)
-$34.37M(+37.0%)
Jun 2015
-
-$6.54M(-41.2%)
-$25.09M(+106.5%)
Mar 2015
-
-$11.12M(+39.8%)
-$12.15M(+356.9%)
Dec 2014
-$2.66M(-78.0%)
-$7.95M(-1617.7%)
-$2.66M(-110.1%)
Sep 2014
-
$524.00K(-91.8%)
$26.20M(-13.5%)
Jun 2014
-
$6.40M(-492.8%)
$30.29M(-385.9%)
Mar 2014
-
-$1.63M(-107.8%)
-$10.59M(-12.5%)
Dec 2013
-$12.11M(-75.3%)
$20.91M(+354.0%)
-$12.11M(-71.4%)
Sep 2013
-
$4.61M(-113.4%)
-$42.37M(-26.0%)
Jun 2013
-
-$34.48M(+994.9%)
-$57.28M(+87.5%)
Mar 2013
-
-$3.15M(-66.3%)
-$30.55M(-37.6%)
Dec 2012
-$48.96M(-244.4%)
-$9.35M(-9.3%)
-$48.96M(+245.2%)
Sep 2012
-
-$10.30M(+32.8%)
-$14.18M(-319.4%)
Jun 2012
-
-$7.76M(-64.0%)
$6.46M(-64.2%)
Mar 2012
-
-$21.55M(-184.8%)
$18.05M(-46.8%)
Dec 2011
$33.90M(+31.3%)
$25.43M(+145.9%)
$33.90M(+300.2%)
Sep 2011
-
$10.34M(+170.0%)
$8.47M(-552.8%)
Jun 2011
-
$3.83M(-167.2%)
-$1.87M(-67.2%)
Mar 2011
-
-$5.70M
-$5.70M
Dec 2010
$25.82M(-191.0%)
-
-
Dec 2009
-$28.39M(-283.4%)
-
-
Dec 2008
$15.48M(+4.2%)
-
-
Dec 2007
$14.85M
-
-

FAQ

  • What is Supernus Pharmaceuticals annual cash flow from investing activities?
  • What is the all time high annual CFI for Supernus Pharmaceuticals?
  • What is Supernus Pharmaceuticals annual CFI year-on-year change?
  • What is Supernus Pharmaceuticals quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Supernus Pharmaceuticals?
  • What is Supernus Pharmaceuticals quarterly CFI year-on-year change?
  • What is Supernus Pharmaceuticals TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Supernus Pharmaceuticals?
  • What is Supernus Pharmaceuticals TTM CFI year-on-year change?

What is Supernus Pharmaceuticals annual cash flow from investing activities?

The current annual CFI of SUPN is -$189.87M

What is the all time high annual CFI for Supernus Pharmaceuticals?

Supernus Pharmaceuticals all-time high annual cash flow from investing activities is $268.73M

What is Supernus Pharmaceuticals annual CFI year-on-year change?

Over the past year, SUPN annual cash flow from investing activities has changed by -$458.60M (-170.65%)

What is Supernus Pharmaceuticals quarterly cash flow from investing activities?

The current quarterly CFI of SUPN is $37.32M

What is the all time high quarterly CFI for Supernus Pharmaceuticals?

Supernus Pharmaceuticals all-time high quarterly cash flow from investing activities is $239.78M

What is Supernus Pharmaceuticals quarterly CFI year-on-year change?

Over the past year, SUPN quarterly cash flow from investing activities has changed by +$88.94M (+172.29%)

What is Supernus Pharmaceuticals TTM cash flow from investing activities?

The current TTM CFI of SUPN is -$100.93M

What is the all time high TTM CFI for Supernus Pharmaceuticals?

Supernus Pharmaceuticals all-time high TTM cash flow from investing activities is $285.94M

What is Supernus Pharmaceuticals TTM CFI year-on-year change?

Over the past year, SUPN TTM cash flow from investing activities has changed by -$78.25M (-345.10%)
On this page